Does UnitedHealthcare Cover Prolia (Denosumab)?

How UnitedHealthcare Classifies Prolia on Its Formulary

Most UnitedHealthcare commercial plans place Prolia on Tier 3, the non-preferred brand tier, which carries the highest cost-sharing for branded drugs that have no generic equivalent. The exact tier can differ across plan types, PPO, HMO, Choice Plus, and Medicare Advantage each maintain separate drug lists, so members should confirm placement through the UHC online formulary tool or by calling the member services number on their insurance card.

For Medicare Part D plans administered by UnitedHealthcare (including AARP MedicineComplete), Prolia may appear on Tier 4 or Tier 5 as a specialty drug, depending on the specific plan year formulary. CMS requires that Medicare Part D formularies cover at least two drugs per therapeutic category, and Prolia's unique RANK-L mechanism means it occupies a distinct niche from bisphosphonates [1].

Denosumab works by inhibiting RANK-L (receptor activator of nuclear factor kappa-B ligand), the cytokine responsible for osteoclast formation, function, and survival [2]. In the key FREEDOM trial (N=7,808), 60 mg denosumab administered subcutaneously every 6 months over 36 months reduced new vertebral fractures by 68% (relative risk 0.32 to 95% CI 0.26, 0.41, P<0.001) compared with placebo, and cut hip fracture risk by 40% (P<0.001) [3]. That fracture-reduction evidence is the clinical foundation on which UHC bases its coverage criteria.

Amgen received FDA approval for Prolia on June 1, 2010, for postmenopausal women at high fracture risk [4]. Subsequent approvals extended the indication to men with osteoporosis, patients on androgen-deprivation therapy for prostate cancer, and patients on aromatase inhibitor therapy for breast cancer [4].

Prior Authorization Criteria UnitedHealthcare Uses for Prolia

Prior authorization (PA) is required on virtually every UHC commercial plan. The criteria below reflect UHC's published clinical coverage determinations and may be updated each plan year. Always request the current criteria document from the UHC Provider Services line (1-800-922-1444) before submitting a PA.

Diagnosis and bone mineral density (BMD) documentation. UHC typically requires a DXA scan showing a T-score of -2.5 or lower at the lumbar spine, total hip, or femoral neck, or a T-score between -1.0 and -2.5 (osteopenia) combined with a 10-year major osteoporotic fracture probability of 20% or higher (or hip fracture probability 3% or higher) as calculated by FRAX [5]. The American Association of Clinical Endocrinology (AACE) 2020 guidelines similarly recommend initiating pharmacologic therapy at these thresholds [6].

Prior therapy documentation. Most UHC plans require documentation of an adequate trial of a bisphosphonate, typically alendronate 70 mg weekly or risedronate 35 mg weekly for at least 12 months, before approving Prolia, unless the patient has a contraindication or documented intolerance such as esophageal dysmotility, renal insufficiency (eGFR <35 mL/min/1.73 m²), or a history of bisphosphonate-related osteonecrosis of the jaw [7]. Crohn's disease, malabsorption syndromes, and inability to remain upright for 30 minutes are also recognized contraindications that UHC reviewers will accept as step-therapy waivers.

Prescriber specialty. Some UHC PA forms require the prescribing provider to be an endocrinologist, rheumatologist, or other specialist with documented expertise in metabolic bone disease, though primary care physicians can often satisfy this requirement by including relevant clinical notes.

PA approval duration and renewal. Initial approvals are typically granted for 12 months (covering two injections). Renewal PAs require documentation that the patient received both scheduled injections, that no serious adverse events occurred (particularly hypocalcemia or osteonecrosis of the jaw), and that continued high fracture risk is present based on interval DXA or clinical assessment [8].

The National Osteoporosis Foundation (now Bone Health and Osteoporosis Foundation) guideline statement reads: "Pharmacologic treatment is recommended for postmenopausal women and men age 50 and older presenting with the following: a hip or vertebral fracture; a T-score of -2.5 or lower; or osteopenia with a 10-year hip fracture probability of 3% or greater or 10-year major osteoporosis-related fracture probability of 20% or greater" [9]. Structuring a PA letter around this language directly maps to UHC's own coverage criteria.

Step Therapy: What UnitedHealthcare Requires Before Approving Prolia

Step therapy, sometimes called "fail-first", means the plan requires a patient to try and fail a lower-cost drug before approving the preferred agent. On UHC commercial plans, the first-line agents in osteoporosis step therapy are almost always generic oral bisphosphonates [10].

Alendronate 70 mg weekly carries a retail cost of roughly $10 to $30 per month at major pharmacies, compared with Prolia's list price of approximately $1,500 per injection. The cost differential explains why UHC and most commercial insurers default to bisphosphonate-first policies.

Accepted step-therapy waiver criteria. UHC will waive the bisphosphonate step in documented circumstances:

• eGFR <35 mL/min/1.73 m² (alendronate and risedronate are contraindicated at this level per FDA labeling) [7]
• Upper GI intolerance confirmed by clinical notes or endoscopy report
• Documented non-response defined as a new fracture or continued BMD decline of more than 5% at the hip or spine after 12 months on a bisphosphonate
• Atypical femoral fracture (AFF) or osteonecrosis of the jaw (ONJ) attributed to bisphosphonate use, confirmed by imaging or pathology

Some state laws restrict the breadth of step therapy. As of 2023, more than 30 states have enacted step-therapy reform statutes requiring insurers to honor documented clinical exceptions [11]. Patients in those states have a statutory right to request a step-therapy exception at the time of initial PA rather than waiting for a denial.

How to Submit a Successful Prolia PA to UnitedHealthcare

A well-constructed PA submission reduces back-and-forth and speeds approval. The following documentation package addresses every UHC clinical criterion in one submission:

1. Completed UHC PA form (available at provider.uhc.com or via Availity)
2. DXA report showing T-score with the specific site (lumbar spine L1-L4, total hip, or femoral neck), scan date, and performing facility
3. FRAX calculation printout from the WHO FRAX tool if T-score is in the osteopenia range [5]
4. Step-therapy evidence: pharmacy fill records for bisphosphonate, dates of fills, and clinical notes documenting the reason for discontinuation or switch
5. Recent metabolic panel including serum calcium and 25-hydroxyvitamin D (denosumab can cause hypocalcemia; uncorrected hypocalcemia is a contraindication per FDA labeling) [4]
6. Fracture history: radiology reports for any vertebral, hip, or wrist fractures
7. Prescriber attestation that the patient meets the FDA-approved indication

Turnaround time for a standard UHC PA is typically 3 business days for non-urgent requests and 1 business day for urgent or concurrent review. For patients already on Prolia who need a renewal PA, urgent review is appropriate because discontinuing denosumab without transitioning to a bisphosphonate causes rapid bone loss and rebound vertebral fractures [12].

The rebound fracture risk after denosumab discontinuation is a distinct safety concern not shared by bisphosphonates. A 2017 analysis published in the Journal of Bone and Mineral Research found that patients who stopped denosumab without a bridging bisphosphonate experienced multiple vertebral fractures at a rate of 7.1% within 12 months of the last injection [12]. Clinicians should document this clinical urgency when requesting expedited renewal PAs.

What Happens After a UnitedHealthcare Denial of Prolia

A denial does not end the process. UHC is required by federal and state law to provide a written denial with the specific clinical rationale, the criteria not met, and instructions for appealing [13].

Level 1 internal appeal. File within 180 days of the denial letter. Submit the same clinical documentation package described above plus a letter from the prescribing physician addressing the specific reason for denial point by point. UHC must respond within 30 days for standard appeals and 72 hours for urgent (expedited) appeals [13].

Level 2 internal appeal. If Level 1 fails, request a second review by a different UHC medical director. The same timelines apply.

External Independent Review Organization (IRO). After exhausting internal appeals, patients have the right to an external review by a state-approved IRO under the ACA's external review provisions [13]. IRO reviewers are independent clinicians not employed by UHC. IRO decisions are binding on the insurer in most states. A 2022 analysis of external review outcomes across commercial insurers found that policyholders win approximately 41% of external reviews for specialty drugs [14].

Peer-to-peer review. Before filing a formal appeal, the prescribing physician can request a peer-to-peer call with the UHC medical director who issued the denial. This call often resolves PA denials without entering the formal appeals process. Request the peer-to-peer within 24 to 48 hours of receiving the denial to preserve the most scheduling flexibility.

State insurance commissioner complaint. If the IRO process fails or is delayed beyond legal timelines, filing a complaint with the state insurance commissioner can compel UHC to comply with required review timelines.

Out-of-Pocket Costs for Prolia With UnitedHealthcare

With a Tier 3 specialty placement and PA approval, member cost-sharing depends on the specific plan's deductible and coinsurance structure.

• During deductible phase: Members pay the full contracted rate, typically $700 to $900 per injection, until the annual deductible is met.
• After deductible, pre-out-of-pocket maximum: Coinsurance of 20% to 40% on a contracted rate near $900 to $1,200 per injection means $180 to $480 per dose.
• After out-of-pocket maximum: $0 for the remainder of the plan year.

Medicare Part D beneficiaries on UHC-administered plans entered the redesigned Part D benefit in 2024, which caps annual out-of-pocket drug spending at $3,400 (2024 cap) and $2,000 (2025 cap) per the Inflation Reduction Act [15]. Prolia's cost before the cap is met can be substantial, but patients who reach the cap pay nothing for the rest of the calendar year.

Manufacturer Savings Programs and Patient Assistance

Amgen Prolia SupportPlus savings card. Commercially insured patients, those with private insurance, not Medicare or Medicaid, may be eligible for the Amgen SupportPlus copay card, which can reduce out-of-pocket costs to as low as $0 per dose for eligible patients, subject to a per-year maximum benefit (Amgen updates this cap annually; verify at amgen.com or via the 1-800-PROLIA-1 line).

The savings card is not valid with any federal or state government program, including Medicare, Medicaid, TRICARE, or CHIP. Using a copay card with a federal program is prohibited under federal anti-kickback statutes.

Amgen Safety Net Foundation. Uninsured or underinsured patients with household incomes at or below 500% of the federal poverty level may qualify for free medication through the Amgen Safety Net Foundation. The application requires income verification and a prescriber signature [4].

UHC Premium Designation and specialty pharmacy. Some UHC plans require Prolia to be dispensed through a UHC-preferred specialty pharmacy (often Optum Rx). Using an out-of-network specialty pharmacy can result in a denial or significantly higher cost-sharing. Confirm the required pharmacy at the time of PA approval.

Clinical Context: Why Prolia Is Prescribed Despite Coverage Hurdles

Prolia's mechanism, targeted RANK-L inhibition, produces fracture-reduction data that justify the coverage fight for appropriate patients. Beyond FREEDOM [3], the long-term FREEDOM Extension study (up to 10 years of denosumab) showed continued gains in BMD with no plateau, with lumbar spine BMD increasing 21.7% from baseline at 10 years [16]. No bisphosphonate trial has demonstrated comparable duration of benefit in a single-drug extension study.

For patients with chronic kidney disease stage 3b to 4 (eGFR 15 to 44 mL/min/1.73 m²), denosumab is often the only guideline-recommended antiresorptive because oral bisphosphonates are contraindicated and IV zoledronic acid requires caution below eGFR 35 [7]. The American Society of Nephrology and KDIGO guidelines acknowledge denosumab as a reasonable option in this population with careful calcium and vitamin D monitoring [17].

The Endocrine Society's 2019 clinical practice guideline on pharmacological management of osteoporosis states: "We recommend denosumab for postmenopausal women with osteoporosis who are at high or imminent risk of fracture, particularly those who cannot tolerate or absorb oral bisphosphonates or have renal impairment" [18]. Citing this guideline language directly in a PA letter or appeal gives the UHC medical reviewer a peer-reviewed, society-endorsed rationale aligned with the coverage criteria.

Bone mineral density monitoring during denosumab therapy follows a standard schedule: DXA at 1 to 2 years after initiation, then every 2 years thereafter if BMD is stable [6]. Documenting this monitoring schedule in clinical notes strengthens renewal PA submissions.

Monitoring Requirements That Support Continued Coverage

UHC renewal PAs for Prolia typically require evidence that the treating clinician is monitoring for the drug's known adverse effects. The FDA label identifies four primary safety concerns [4]:

1. Hypocalcemia: Serum calcium must be checked before each injection. Pre-existing hypocalcemia is a contraindication. Supplemental calcium (1 to 000 mg daily) and vitamin D (at least 400 IU daily, with most guidelines recommending 800 to 2 to 000 IU) are required co-prescriptions.
2. Osteonecrosis of the jaw (ONJ): Incidence in the osteoporosis population is estimated at 0 to 0.05% per patient-year, lower than in oncologic doses [19]. Dental examination before starting denosumab is recommended.
3. Atypical femoral fractures (AFF): Rare but reported with long-term use. Patients reporting thigh or groin pain should undergo femoral X-ray [19].
4. Serious infections: Cellulitis and urinary tract infections occurred more frequently in the denosumab arm of FREEDOM (P<0.001) [3]. Patients with active infections should delay injection.

Documenting routine monitoring of these parameters in clinical notes creates a clear record that supports both clinical appropriateness and PA renewal approvals.

Prolia vs. Other UHC-Covered Osteoporosis Agents: Coverage Comparison

Understanding where Prolia sits relative to other covered agents helps prescribers and patients make informed decisions about the coverage pathway.

| Drug | Typical UHC Tier | PA Required | Step Therapy Required | |------|-----------------|-------------|----------------------| | Alendronate (generic) | Tier 1 | No | First-line | | Risedronate (generic) | Tier 1 | No | First-line | | Zoledronic acid IV (generic) | Tier 2 or medical benefit | Yes | After oral bisphosphonate failure | | Prolia (denosumab) | Tier 3 | Yes | After bisphosphonate | | Evenity (romosozumab) | Tier 4 specialty | Yes | After bisphosphonate and often after denosumab | | Forteo (teriparatide) | Tier 4 specialty | Yes | After antiresorptive failure |

Zoledronic acid 5 mg IV (Reclast) may be administered as a medical benefit under the member's medical plan rather than the pharmacy benefit, which changes the cost-sharing structure. In that pathway, UHC processes the claim under facility or physician fee schedules, and the member's medical deductible and coinsurance apply instead of the drug benefit tier.